Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Sector-22, Kharghar, Navi Mumbai, 410210, India.
Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, Maharashtra, 400094, India.
Eur J Drug Metab Pharmacokinet. 2023 Nov;48(6):657-663. doi: 10.1007/s13318-023-00851-7. Epub 2023 Sep 12.
Moderate malnutrition is a common problem in young children. It is observed that severe malnutrition affects the pharmacokinetics of chemotherapy drugs in pediatric cancer patients, but moderate malnutrition is not well studied in this context.
In this study, we aimed to understand how moderate malnutrition affects the pharmacokinetics of two chemotherapy drugs, etoposide and vincristine, using a murine model of early age moderate malnutrition.
We developed a murine model of moderate childhood malnutrition by subjecting freshly weaned Sprague-Dawley rats to 8% protein diet for 8 weeks. In two separate experiments, we administered etoposide and vincristine (N = 8 for etoposide and N = 12 for vincristine each in protein deficient and control groups) through tail vein injection for pharmacokinetics study.
We found ~ 60% increase in area under the concentration-time curve (AUC) of etoposide in malnourished animals as compared to well-nourished animals. Furthermore, clearance, volume of distribution, and half-life were decreased by ~ 37, 53, and 24%, respectively, in malnourished animals. Pharmacokinetic parameters of vincristine showed only marginal differences between well-nourished and malnourished groups.
Our results suggest that while moderate malnutrition significantly affects the pharmacokinetics of etoposide, pharmacokinetics of vincristine remain unchanged. Since chemotherapy drugs have a narrow therapeutic index, the difference in AUC observed in our study might explain the increased toxicity of etoposide in malnourished pediatric cancer patients. This brings forth a need for robust clinical studies to validate our findings and optimize dose for malnourished patients.
中度营养不良是幼儿中常见的问题。据观察,严重营养不良会影响儿科癌症患者化疗药物的药代动力学,但在这种情况下,中度营养不良尚未得到充分研究。
在这项研究中,我们旨在使用幼年中度营养不良的小鼠模型,了解中度营养不良如何影响依托泊苷和长春新碱这两种化疗药物的药代动力学。
我们通过对新生的 Sprague-Dawley 大鼠施以 8%蛋白质饮食 8 周,建立了一种中度儿童营养不良的小鼠模型。在两项独立的实验中,我们通过尾静脉注射给予依托泊苷和长春新碱(每组蛋白质缺乏组和对照组各有 8 只用于依托泊苷和 12 只用于长春新碱进行药代动力学研究)。
与营养良好的动物相比,营养不良的动物中依托泊苷的浓度-时间曲线下面积(AUC)增加了约 60%。此外,在营养不良的动物中,清除率、分布容积和半衰期分别降低了约 37%、53%和 24%。依托泊苷的药代动力学参数在营养良好和营养不良的组之间仅显示出微小差异。
我们的结果表明,虽然中度营养不良显著影响依托泊苷的药代动力学,但长春新碱的药代动力学保持不变。由于化疗药物的治疗指数较窄,我们研究中观察到的 AUC 差异可能解释了营养不良的儿科癌症患者中依托泊苷毒性增加的原因。这提出了需要进行强有力的临床研究来验证我们的发现并优化营养不良患者的剂量。